Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/13—Amines
  • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
  • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/02—Inorganic compounds
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
  • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
  • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
  • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
  • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
  • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/0012—Galenical forms characterised by the site of application
  • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
  • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/08—Solutions
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/04—Centrally acting analgesics, e.g. opioids
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
  • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
  • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
  • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
  • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

• the invention relates to an aqueous pharmaceutical composition containing tapentadol or a physiologically acceptable salt thereof and being adapted for oral administration.
• Tapentadol is a centrally-acting analgesic with a dual mode of action as an agonist at the ⁇ -opioid receptor and as a norepinephrine reuptake inhibitor (cf. T. M. Tzschentke et al., Drugs of the future, 2006, 12, 1053-1061).
• Solid oral dosage forms of tapentadol are known from the prior art, e.g. WO 02/067651, WO 03/035053, WO 2006/002886, WO 2007/128412, WO 2007/128413, WO 2008/110323, WO 2009/092601, WO 2009/067703, and US 2007-128412.
• solid oral dosage forms containing tapentadol are not satisfactory in every respect and there is a demand of pharmaceutical formulations which have advantages compared to the known solid oral dosage forms.
• the stability of the active ingredient in the final product is a primary concern to the formulator.
• drug substances are less stable in aqueous media than solid dosage forms, and it is important to properly stabilize and preserve liquid aqueous formulations such as solutions, suspensions, and emulsions.
• Acid-base reactions, acid or base catalysis, oxidation, and reduction can occur in these products. These reactions can arise from drug substance-ingredient interactions, ingredient-ingredient interactions or container-product interactions. For pH sensitive compounds, any of these interactions may alter the pH and may cause precipitation.
• Oxidative labile drug substances or vitamins, essential oils, and almost all fats and oils can be oxidized by auto-oxidation. Such reactions can be initiated by heat, light, peroxides, or other labile compounds or heavy metals such as copper or iron.
• antioxidants may retard or delay oxidation by rapidly reacting with free radicals as they are formed (quenching).
• Common antioxidants include propyl, octyl and dodecylesters of gallic acid, butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), ascorbic acid, sodium ascorbate, monothioglycerol, potassium or sodium metabisulfite, propionic acid, propyl gallate, sodium bisulfite, sodium sulfite, and the tocopherols or vitamin E.
• BHA butylated hydroxyanisole
• BHT butylated hydroxytoluene
• ascorbic acid sodium ascorbate
• monothioglycerol monothioglycerol
• potassium or sodium metabisulfite propionic acid
• propyl gallate sodium bisulfite, sodium sulfite, and the tocopherols or vitamin E.
• liquid and semisolid preparations In addition to stabilization of pharmaceutical preparations against chemical and physical degradation, liquid and semisolid preparations, particularly multiple dosed preparations, must usually be protected against microbial contamination.
• aqueous solutions, syrups, emulsions, and suspensions often provide excellent growth media for microorganisms such as molds, yeast, and bacteria (e.g. Pseudomonas Aeruginosa, E. Coll, Salmonella spp., Staphylococcus aureus, Candida albicans, Aspergillus niger ). Contamination by these microorganisms may occur during manufacturing or when a dose is taken from a multiple dosed formulation. Growth of the microorganisms occurs when a sufficient amount of water is present in the formulation.
• Ophthalmic and injectable preparations are typically sterilized by autoclaving or filtration. However, many of them require the presence of an antimicrobial preservative to maintain aseptic conditions throughout their stated shelf life, specifically for multiple dosed preparations.
• a preservative When a preservative is required, its selection is based upon several considerations, in particular the site of use whether internal, external or ophthalmic (for further details it can be referred to e.g. Remington, The Science and Practice of Pharmacy, 21 st edition, Lippincott Williams & Wilkins, 2005).
• liquid formulations for oral administration contain parabens as preservatives, e.g. methyl paraben (methyl-4-hydroxybenzoate) and propyl paraben (propyl-4-hydroxybenzoate).
• parabens e.g. methyl paraben (methyl-4-hydroxybenzoate) and propyl paraben (propyl-4-hydroxybenzoate).
• methyl paraben methyl-4-hydroxybenzoate
• propyl paraben propyl paraben (propyl-4-hydroxybenzoate).
• ben-u-ron® Cetirizin-ratiopharm®
• Pipamperon HEXAL® Sedotussin®
• TALOXA® Sedotussin®
• Truxal® XUSAL®
• talvosilen® talvosilen®
• Timonil® Other commercialized liquid formulations contain sorbic acid or its potassium salt as preservative, e.g. ibuprofen liquid
• the preservatives benzalkonium chloride and potassium sorbate are also widely used e.g. in nasal drops and sprays. Recently, side effects resulting from mucosal damage caused by benzalkonium chloride and potassium sorbate were reported (cf. C. Y. Ho et al., Am J Rhinol. 2008, 22(2), 125-9). As far as hypersensitivity reactions of preservatives in topical ophthalmic therapies are concerned, quaternary ammoniums (benzalkonium chloride) are commonly associated with irritant toxic reactions whereas the organomercurials (thimerosal) and the alcohols (chlorobutanol) have high associations, respectively, with allergic responses (cf. J.
• compositions for oral administration that exhibit a sufficient shelf life and in use stability in the absence of preservatives or at least in the presence of comparatively low quantities thereof.
• WO 2008/110323 discloses a composition for parenteral administration of 20 g (1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol hydrochloride in 1 L water for injection purposes which has been isotonized by addition of NaCl.
• the pharmaceutical formulations should not have the above preservative based side effects that are typically observed with pharmaceutical formulations containing preservatives such as allergic reactions.
• a first aspect of the invention relates to an aqueous pharmaceutical composition containing tapentadol or a physiologically acceptable salt thereof and being adapted for oral administration.
• the term “tapentadol” includes the free base ((1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol) as well as any physiologically acceptable salt thereof, particularly the hydrochloride ((1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol hydrochloride).
• the term “tapentadol” does not only refer to the free base but also to any physiologically acceptable salt. Further, unless expressly stated otherwise, all amounts, contents and concentrations are equivalents related to tapentadol free base.
• composition according to the invention is aqueous.
• aqueous means that its water content is preferably above the typical water content of solid pharmaceutical dosage forms which are humidified from the atmosphere due to the more or less pronounced hygroscopic properties of their constituents.
• the water content of the composition is at least 0.5 wt.-%, more preferably at least 1.0 wt.-%, still more preferably at least 2.0 wt.-%, yet more preferably at least 3.0 wt.-%, most preferably at least 4.0 wt.-% and in particular at least 5.0 wt.-%, based on the total weight of the composition.
• the water content of the composition is at least 5 wt.-%, more preferably at least 10 wt.-%, still more preferably at least 20 wt.-%, yet more preferably at least 30 wt.-%, most preferably at least 40 wt.-% and in particular at least 50 wt.-%, based on the total weight of the composition.
• the water content of the composition is within the range of 35 ⁇ 30 wt.-%, more preferably 35 ⁇ 25 wt.-%, still more preferably 35 ⁇ 20 wt.-%, yet more preferably 35 ⁇ 15 wt.-%, most preferably 35 ⁇ 10 wt.-% and in particular 35 ⁇ 5 wt.-%, based on the total weight of the composition.
• the water content of the composition is within the range of 45 ⁇ 30 wt.-%, more preferably 45 ⁇ 25 wt.-%, still more preferably 45 ⁇ 20 wt.-%, yet more preferably 45 ⁇ 15 wt.-%, most preferably 45 ⁇ 10 wt.-% and in particular 45 ⁇ 5 wt.-%, based on the total weight of the composition.
• the water content of the composition is within the range of 55 ⁇ 30 wt.-%, more preferably 55 ⁇ 25 wt.-%, still more preferably 55 ⁇ 20 wt.-%, yet more preferably 55 ⁇ 15 wt.-%, most preferably 55 ⁇ 10 wt.-% and in particular 55 ⁇ 5 wt.-%, based on the total weight of the composition.
• the water content of the composition is within the range of 65 ⁇ 30 wt.-%, more preferably 65 ⁇ 25 wt.-%, still more preferably 65 ⁇ 20 wt.-%, yet more preferably 65 ⁇ 15 wt.-%, most preferably 65 ⁇ 10 wt.-% and in particular 65 ⁇ 5 wt.-%, based on the total weight of the composition.
• the water content of the composition is within the range of 75 ⁇ 24 wt.-%, more preferably 75 ⁇ 22 wt.-%, still more preferably 75 ⁇ 20 wt.-%, yet more preferably 75 ⁇ 15 wt.-%, most preferably 75 ⁇ 10 wt.-% and in particular 75 ⁇ 5 wt.-%, based on the total weight of the composition.
• the water content of the composition is within the range of 85 ⁇ 14 wt.-%, more preferably 85 ⁇ 12 wt.-%, still more preferably 85 ⁇ 10 wt.-%, most preferably 85 ⁇ 7.5 wt.-% and in particular 85 ⁇ 5 wt.-%, based on the total weight of the composition.
• the water content of the composition is within the range of 95 ⁇ 4.75 wt.-%, more preferably 95 ⁇ 4.5 wt.-%, still more preferably 95 ⁇ 4 wt.-%, yet more preferably 95 ⁇ 3.5 wt.-%, most preferably 95 ⁇ 3 wt.-% and in particular 95 ⁇ 2.5 wt.-%, based on the total weight of the composition.
• the water content of the composition is within the range of from 75 to 99.99 wt.-%, more preferably 80 to 99.98 wt.-%, still more preferably 85 to 99.95 wt.-%, yet more preferably 90 to 99.9 wt.-%, most preferably 95 to 99.7 wt.-% and in particular 96.5 to 99.5 wt.-%, based on the total weight of the composition.
• the composition has a viscosity within the range of 15 ⁇ 12 mPas, more preferably 15 ⁇ 10 mPas, still more preferably 15 ⁇ 8 mPas, yet more preferably 15 ⁇ 6 mPas, most preferably 15 ⁇ 4 mPas, and in particular 15 ⁇ 2 mPas.
• the composition has a viscosity within the range of 30 ⁇ 28 mPas, more preferably 30 ⁇ 20 mPas, still more preferably 30 ⁇ 16 mPas, yet more preferably 30 ⁇ 12 mPas, most preferably 30 ⁇ 8 mPas, and in particular 30 ⁇ 4 mPas.
• the composition has a viscosity within the range of 60 ⁇ 56 mPas, more preferably 60 ⁇ 40 mPas, still more preferably 60 ⁇ 32 mPas, yet more preferably 60 ⁇ 24 mPas, most preferably 60 ⁇ 16 mPas, and in particular 60 ⁇ 8 mPas.
• the composition has a viscosity within the range of 120 ⁇ 112 mPas, more preferably 120 ⁇ 80 mPas, still more preferably 120 ⁇ 64 mPas, yet more preferably 120 ⁇ 48 mPas, most preferably 120 ⁇ 32 mPas, and in particular 120 ⁇ 16 mPas.
• the composition has a viscosity within the range of 240 ⁇ 224 mPas, more preferably 240 ⁇ 160 mPas, still more preferably 240 ⁇ 128 mPas, yet more preferably 240 ⁇ 96 mPas, most preferably 240 ⁇ 64 mPas, and in particular 240 ⁇ 32 mPas.
• the composition has a viscosity within the range of 500 ⁇ 400 mPas, more preferably 500 ⁇ 300 mPas, still more preferably 500 ⁇ 200 mPas, yet more preferably 500 ⁇ 150 mPas, most preferably 500 ⁇ 100 mPas, and in particular 500 ⁇ 50 mPas.
• the viscosity is measured at room temperature.
• composition according to the invention may contain further solvents.
• Further suitable solvents include all physiologically acceptable substances that are normally liquid at ambient or room temperatures.
• the further solvent is water-soluble or water-miscible.
• Further solvents may be selected from the group consisting of propylene glycol, ethanol, poly(ethylene glycol) or PEG, propylene carbonate, diethylene glycol monoethyl ether, poloxamer, glycofurol, glycerol, and mixtures thereof.
• Further solvents also include tensides (emulsifiers) and/or fats.
• the composition contains a tenside. In a preferred embodiment, the composition contains a single tenside. In another preferred embodiment, the composition contains a mixture of two or more tensides.
• the tenside has a hydrophilic-lipophilic balance (HLB) of at least 10. More preferably, the hydrophilic-lipophilic balance (HLB) is at least 12. Most preferably, the hydrophilic-lipophilic balance (HLB) ranges within 14 and 16.
• the tenside can be an ionic tenside, amphoteric tenside or non-ionic tenside.
• the tenside is ionic, in particular anionic.
• Suitable anionic ionic tensides include but are not limited to sodium lauryl sulfate (sodium dodecyl sulfate), sodium cetyl stearyl sulfate, sodium dioctylsulfosuccinate (docusate sodium); and the corresponding potassium or calcium salts thereof.
• the tenside is non-ionic. Suitable non-ionic tensides include but are not limited to
• fats examples include glycerol monostearate, glycerol monopalmitate, stearic acid, diglycol stearate, glycerol trioleate, carnauba wax, bees wax, cetylstearyl alcohol and the like.
• water is the only liquid constituent of the composition according to the invention.
• composition according to the invention is adapted for oral administration.
• oral administration includes every administration through the oral cavity such as peroral, sublingual, buccal, and the like.
• oral administration has the purpose of systemically administering tapentadol upon swallowing.
• composition includes any pharmaceutical preparation or formulation that is customized for being administered to a human being or animal.
• the composition contains one or more physiologically acceptable carriers, preferably water, and/or excipients.
• the pharmaceutical composition may be a subunit of a pharmaceutical dosage form, e.g. the liquid core of a capsule.
• the composition according to the invention is buffered, i.e. contains one or more buffers and buffer systems (i.e. conjugate acid-base-pairs), respectively.
• buffer systems are derived from the following acids: organic acids such as acetic acid, propionic acid, maleic acid, fumaric acid, malonic acid, malic acid, mandelic acid, citric acid, tartric acid; or inorganic acids such as phosphoric acid. Citric acid or citric acid monohydrate are particularly preferred.
• the buffer system constitutes of said acid and its conjugate base.
• the composition has a pH value within the range of from 3.0 to 6.5, more preferably 3.0 to 6.0, still more preferably 3.0 to 5.5, yet more preferably 3.0 to 5.0, most preferably 3.2 to 4.8 and in particular 3.4 to 4.6.
• Higher pH values are also possible, e.g. 3.0 to 9.0, 3.0 to 8.5, 3.0 to 8.0 or 3.0 to 7.5.
• the composition has a pH value within the range of 3.0 ⁇ 1.4 or 3.0 ⁇ 1.3, more preferably 3.0 ⁇ 1.2 or 3.0 ⁇ 1.1, still more preferably 3.0 ⁇ 1.0 or 3.0 ⁇ 0.9, yet more preferably 3.0 ⁇ 0.8 or 3.0 ⁇ 0.7, even more preferably 3.0 ⁇ 0.6 or 3.0 ⁇ 0.5, most preferably 3.0 ⁇ 0.4 or 3.0 ⁇ 0.3, and in particular 3.0 ⁇ 0.2 or 3.0 ⁇ 0.1.
• the composition has a pH value within the range of 3.5 ⁇ 1.4 or 3.5 ⁇ 1.3, more preferably 3.5 ⁇ 1.2 or 3.5 ⁇ 1.1, still more preferably 3.5 ⁇ 1.0 or 3.5 ⁇ 0.9, yet more preferably 3.5 ⁇ 0.8 or 3.5 ⁇ 0.7, even more preferably 3.5 ⁇ 0.6 or 3.5 ⁇ 0.5, most preferably 3.5 ⁇ 0.4 or 3.5 ⁇ 0.3, and in particular 3.5 ⁇ 0.2 or 3.5 ⁇ 0.1.
• the composition has a pH value within the range of 4.0 ⁇ 1.4 or 4.0 ⁇ 1.3, more preferably 4.0 ⁇ 1.2 or 4.0 ⁇ 1.1, still more preferably 4.0 ⁇ 1.0 or 4.0 ⁇ 0.9, yet more preferably 4.0 ⁇ 0.8 or 4.0 ⁇ 0.7, even more preferably 4.0 ⁇ 0.6 or 4.0 ⁇ 0.5, most preferably 4.0 ⁇ 0.4 or 4.0 ⁇ 0.3, and in particular 4.0 ⁇ 0.2 or 4.0 ⁇ 0.1.
• the composition has a pH value within the range of 4.5 ⁇ 1.4 or 4.5 ⁇ 1.3, more preferably 4.5 ⁇ 1.2 or 4.5 ⁇ 1.1, still more preferably 4.5 ⁇ 1.0 or 4.5 ⁇ 0.9, yet more preferably 4.5 ⁇ 0.8 or 4.5 ⁇ 0.7, even more preferably 4.5 ⁇ 0.6 or 4.5 ⁇ 0.5, most preferably 4.5 ⁇ 0.4 or 4.5 ⁇ 0.3, and in particular 4.5 ⁇ 0.2 or 4.5 ⁇ 0.1.
• the composition has a pH value within the range of 5.0 ⁇ 1.4 or 5.0 ⁇ 1.3, more preferably 5.0 ⁇ 1.2 or 5.0 ⁇ 1.1, still more preferably 5.0 ⁇ 1.0 or 5.0 ⁇ 0.9, yet more preferably 5.0 ⁇ 0.8 or 5.0 ⁇ 0.7, even more preferably 5.0 ⁇ 0.6 or 5.0 ⁇ 0.5, most preferably 5.0 ⁇ 0.4 or 5.0 ⁇ 0.3, and in particular 5.0 ⁇ 0.2 or 5.0 ⁇ 0.1.
• the composition has a pH value within the range of 5.5 ⁇ 1.4 or 5.5 ⁇ 1.3, more preferably 5.5 ⁇ 1.2 or 5.5 ⁇ 1.1, still more preferably 5.5 ⁇ 1.0 or 5.5 ⁇ 0.9, yet more preferably 5.5 ⁇ 0.8 or 5.5 ⁇ 0.7, even more preferably 5.5 ⁇ 0.6 or 5.5 ⁇ 0.5, most preferably 5.5 ⁇ 0.4 or 5.5 ⁇ 0.3, and in particular 5.5 ⁇ 0.2 or 5.5 ⁇ 0.1.
• the composition has a pH value within the range of 6.0 ⁇ 1.4 or 6.0 ⁇ 1.3, more preferably 6.0 ⁇ 1.2 or 6.0 ⁇ 1.1, still more preferably 6.0 ⁇ 1.0 or 6.0 ⁇ 0.9, yet more preferably 6.0 ⁇ 0.8 or 6.0 ⁇ 0.7, even more preferably 6.0 ⁇ 0.6 or 6.0 ⁇ 0.5, most preferably 6.0 ⁇ 0.4 or 6.0 ⁇ 0.3, and in particular 6.0 ⁇ 0.2 or 6.0 ⁇ 0.1.
• the composition has a pH value within the range of 6.5 ⁇ 1.4 or 6.5 ⁇ 1.3, more preferably 6.5 ⁇ 1.2 or 6.5 ⁇ 1.1, still more preferably 6.5 ⁇ 1.0 or 6.5 ⁇ 0.9, yet more preferably 6.5 ⁇ 0.8 or 6.5 ⁇ 0.7, even more preferably 6.5 ⁇ 0.6 or 6.5 ⁇ 0.5, most preferably 6.5 ⁇ 0.4 or 6.5 ⁇ 0.3, and in particular 6.5 ⁇ 0.2 or 6.5 ⁇ 0.1.
• the composition has a pH value within the range of 7.0 ⁇ 1.4 or 7.0 ⁇ 1.3, more preferably 7.0 ⁇ 1.2 or 7.0 ⁇ 1.1, still more preferably 7.0 ⁇ 1.0 or 7.0 ⁇ 0.9, yet more preferably 7.0 ⁇ 0.8 or 7.0 ⁇ 0.7, even more preferably 7.0 ⁇ 0.6 or 7.0 ⁇ 0.5, most preferably 7.0 ⁇ 0.4 or 7.0 ⁇ 0.3, and in particular 7.0 ⁇ 0.2 or 7.0 ⁇ 0.1.
• the composition has a pH value within the range of 7.5 ⁇ 1.4 or 7.5 ⁇ 1.3, more preferably 7.5 ⁇ 1.2 or 7.5 ⁇ 1.1, still more preferably 7.5 ⁇ 1.0 or 7.5 ⁇ 0.9, yet more preferably 7.5 ⁇ 0.8 or 7.5 ⁇ 0.7, even more preferably 7.5 ⁇ 0.6 or 7.5 ⁇ 0.5, most preferably 7.5 ⁇ 0.4 or 7.5 ⁇ 0.3, and in particular 7.5 ⁇ 0.2 or 7.5 ⁇ 0.1.
• the composition has a pH value within the range of 8.0 ⁇ 1.4 or 8.0 ⁇ 1.3, more preferably 8.0 ⁇ 1.2 or 8.0 ⁇ 1.1, still more preferably 8.0 ⁇ 1.0 or 8.0 ⁇ 0.9, yet more preferably 8.0 ⁇ 0.8 or 8.0 ⁇ 0.7, even more preferably 8.0 ⁇ 0.6 or 8.0 ⁇ 0.5, most preferably 8.0 ⁇ 0.4 or 8.0 ⁇ 0.3, and in particular 8.0 ⁇ 0.2 or 8.0 ⁇ 0.1.
• the composition has a pH value within the range of 8.5 ⁇ 1.4 or 8.5 ⁇ 1.3, more preferably 8.5 ⁇ 1.2 or 8.5 ⁇ 1.1, still more preferably 8.5 ⁇ 1.0 or 8.5 ⁇ 0.9, yet more preferably 8.5 ⁇ 0.8 or 8.5 ⁇ 0.7, even more preferably 8.5 ⁇ 0.6 or 8.5 ⁇ 0.5, most preferably 8.5 ⁇ 0.4 or 8.5 ⁇ 0.3, and in particular 8.5 ⁇ 0.2 or 8.5 ⁇ 0.1.
• the composition has a pH value within the range of 9.0 ⁇ 1.4 or 9.0 ⁇ 1.3, more preferably 9.0 ⁇ 1.2 or 9.0 ⁇ 1.1, still more preferably 9.0 ⁇ 1.0 or 9.0 ⁇ 0.9, yet more preferably 9.0 ⁇ 0.8 or 9.0 ⁇ 0.7, even more preferably 9.0 ⁇ 0.6 or 9.0 ⁇ 0.5, most preferably 9.0 ⁇ 0.4 or 9.0 ⁇ 0.3, and in particular 9.0 ⁇ 0.2 or 9.0 ⁇ 0.1.
• the concentration of the buffer and buffer system is adjusted to provide a sufficient buffer capacity.
• the content of the buffer and buffer system is within the range of from 0.0001 to 5.0 wt.-%, more preferably 0.0005 to 4.5 wt.-%, still more preferably 0.001 to 4.0 wt.-%, yet more preferably 0.005 to 3.5 wt.-%, most preferably 0.01 to 3.0 wt.-% and in particular 0.05 to 2.5 wt.-%, based on the total weight of the composition.
• the buffer and buffer system respectively, preferably citric acid or its monohydrate, has a concentration within the range of 1.0 ⁇ 0.6 mg/mL, more preferably 1.0 ⁇ 0.5 mg/mL, still more preferably 1.0 ⁇ 0.4 mg/mL, yet more preferably 1.0 ⁇ 0.3 mg/mL, most preferably 1.0 ⁇ 0.2 mg/mL, and in particular 1.0 ⁇ 0.1 mg/mL, based on the total volume of the composition.
• the buffer and buffer system respectively, preferably citric acid or its monohydrate, has a concentration within the range of 1.5 ⁇ 0.6 mg/mL, more preferably 1.5 ⁇ 0.5 mg/mL, still more preferably 1.5 ⁇ 0.4 mg/mL, yet more preferably 1.5 ⁇ 0.3 mg/mL, most preferably 1.5 ⁇ 0.2 mg/mL, and in particular 1.5 ⁇ 0.1 mg/mL, based on the total volume of the composition.
• the buffer and buffer system respectively, preferably citric acid or its monohydrate, has a concentration within the range of 2.0 ⁇ 0.6 mg/mL, more preferably 2.0 ⁇ 0.5 mg/mL, still more preferably 2.0 ⁇ 0.4 mg/mL, yet more preferably 2.0 ⁇ 0.3 mg/mL, most preferably 2.0 ⁇ 0.2 mg/mL, and in particular 2.0 ⁇ 0.1 mg/mL, based on the total volume of the composition.
• the buffer and buffer system respectively, preferably citric acid or its monohydrate, has a concentration within the range of 2.5 ⁇ 0.6 mg/mL, more preferably 2.5 ⁇ 0.5 mg/mL, still more preferably 2.5 ⁇ 0.4 mg/mL, yet more preferably 2.5 ⁇ 0.3 mg/mL, most preferably 2.5 ⁇ 0.2 mg/mL, and in particular 2.5 ⁇ 0.1 mg/mL, based on the total volume of the composition.
• citric acid is a triprotonic acid so that it forms the conjugate acid-base pairs citric acid-dihydrogencitrate, dihydrogencitrate-hydrogencitrate and hydrogencitrate-citrate.
• any of citric acid, dihydrogencitrate and hydrogencitrate can be the acid of a buffer system with the conjugate base.
• the expression “buffer and buffer system, respectively” preferably refers to the quantity of both, the acid and its conjugate base.
• a buffer system e.g. the conjugate system citric acid/sodium dihydrogencitrate can be established either by adding citric acid and an appropriate amount of sodium hydroxide or citric acid and sodium dihydrogencitrate as such.
• the content of tapentadol is within the range of from 0.01 to 50 wt.-%, more preferably 0.05 to 45 wt.-%, still more preferably 0.1 to 40 wt.-%, yet more preferably 0.5 to 35 wt.-%, most preferably 1.0 to 30 wt.-% and in particular 5.0 to 25 wt.-%, based on the total weight of the composition.
• the content of tapentadol is within the range of from 0.0001 to 5.0 wt.-%, more preferably 0.0005 to 4.5 wt.-%, still more preferably 0.001 to 4.0 wt.-%, yet more preferably 0.005 to 3.5 wt.-%, most preferably 0.01 to 3.0 wt.-% and in particular 0.05 to 2.5 wt.-%, based on the total weight of the composition.
• the content of tapentadol is within the range of from 0.01 to 3.0 wt.-%, more preferably 0.05 to 2.8 wt.-%, still more preferably 0.1 to 2.6 wt.-%, yet more preferably 0.2 to 2.4 wt.-%, most preferably 0.3 to 2.2 wt.-% and in particular 0.4 to 2.0 wt.-%, based on the total weight of the composition.
• the concentration of tapentadol is equal or below 200 mg/mL, more preferably equal or below 150 mg/mL, still more preferably equal or below 100 mg/mL, yet more preferably equal or below 75 mg/mL, and most preferably equal or below 50 mg/mL, and in particular equal or below 30 mg/mL, based on the total volume of the composition.
• the concentration of tapentadol is within the range of from 0.5 to 200 mg/mL, more preferably within the range of from 1.0 to 150 mg/mL, still more preferably within the range of from 1.5 to 100 mg/mL, yet more preferably within the range of from 2.0 to 75 mg/mL, most preferably within the range of from 2.5 to 50 mg/mL, and in particular within the range of from 3.0 to 25 mg/mL based on the total volume of the composition.
• the concentration of tapentadol is equal or below 20 mg/mL, based on the total volume of the composition.
• the concentration of tapentadol is within the range of 20 ⁇ 6 mg/mL, more preferably 20 ⁇ 5 mg/mL, still more preferably 20 ⁇ 4 mg/mL, yet more preferably 20 ⁇ 3 mg/mL, most preferably 20 ⁇ 2 mg/mL, and in particular 20 ⁇ 1 mg/mL, based on the total volume of the composition.
• the concentration of tapentadol is within the range of 17.5 ⁇ 6 mg/mL, more preferably 17.5 ⁇ 5 mg/mL, still more preferably 17.5 ⁇ 4 mg/mL, yet more preferably 17.5 ⁇ 3 mg/mL, most preferably 17.5 ⁇ 2 mg/mL, and in particular 17.5 ⁇ 1 mg/mL, based on the total volume of the composition.
• the concentration of tapentadol is within the range of 15 ⁇ 6 mg/mL, more preferably 15 ⁇ 5 mg/mL, still more preferably 15 ⁇ 4 mg/mL, yet more preferably 15 ⁇ 3 mg/mL, most preferably 15 ⁇ 2 mg/mL, and in particular 15 ⁇ 1 mg/mL, based on the total volume of the composition.
• the concentration of tapentadol is within the range of 12.5 ⁇ 6 mg/mL, more preferably 12.5 ⁇ 5 mg/mL, still more preferably 12.5 ⁇ 4 mg/mL, yet more preferably 12.5 ⁇ 3 mg/mL, most preferably 12.5 ⁇ 2 mg/mL, and in particular 12.5 ⁇ 1 mg/mL, based on the total volume of the composition.
• the concentration of tapentadol is within the range of 10 ⁇ 6 mg/mL, more preferably 10 ⁇ 5 mg/mL, still more preferably 10 ⁇ 4 mg/mL, yet more preferably 10 ⁇ 3 mg/mL, most preferably 10 ⁇ 2 mg/mL, and in particular 10 ⁇ 1 mg/mL, based on the total volume of the composition.
• the concentration of tapentadol is within the range of 7.5 ⁇ 6 mg/mL, more preferably 7.5 ⁇ 5 mg/mL, still more preferably 7.5 ⁇ 4 mg/mL, yet more preferably 7.5 ⁇ 3 mg/mL, most preferably 7.5 ⁇ 2 mg/mL, and in particular 7.5 ⁇ 1 mg/mL, based on the total volume of the composition.
• the concentration of tapentadol is within the range of 4 ⁇ 3 mg/mL, more preferably 4 ⁇ 2.5 mg/mL, still more preferably 4 ⁇ 2 mg/mL, yet more preferably 4 ⁇ 1.5 mg/mL, most preferably 4 ⁇ 1 mg/mL, and in particular 4 ⁇ 0.5 mg/mL, based on the total volume of the composition.
• the concentration of tapentadol is equal or above 20 mg/mL, based on the total volume of the composition.
• the concentration of tapentadol is within the range of 22.5 ⁇ 6 mg/mL, more preferably 22.5 ⁇ 5 mg/mL, still more preferably 22.5 ⁇ 4 mg/mL, yet more preferably 22.5 ⁇ 3 mg/mL, most preferably 22.5 ⁇ 2 mg/mL, and in particular 22.5 ⁇ 1 mg/mL, based on the total volume of the composition.
• the concentration of tapentadol is within the range of 25 ⁇ 6 mg/mL, more preferably 25 ⁇ 5 mg/mL, still more preferably 25 ⁇ 4 mg/mL, yet more preferably 25 ⁇ 3 mg/mL, most preferably 25 ⁇ 2 mg/mL, and in particular 25 ⁇ 1 mg/mL, based on the total volume of the composition.
• the concentration of tapentadol is within the range of 27.5 ⁇ 6 mg/mL, more preferably 27.5 ⁇ 5 mg/mL, still more preferably 27.5 ⁇ 4 mg/mL, yet more preferably 27.5 ⁇ 3 mg/mL, most preferably 27.5 ⁇ 2 mg/mL, and in particular 27.5 ⁇ 1 mg/mL, based on the total volume of the composition.
• the concentration of tapentadol is within the range of 30 ⁇ 6 mg/mL, more preferably 30 ⁇ 5 mg/mL, still more preferably 30 ⁇ 4 mg/mL, yet more preferably 30 ⁇ 3 mg/mL, most preferably 30 ⁇ 2 mg/mL, and in particular 30 ⁇ 1 mg/mL, based on the total volume of the composition.
• the concentration of tapentadol is within the range of 32.5 ⁇ 6 mg/mL, more preferably 32.5 ⁇ 5 mg/mL, still more preferably 32.5 ⁇ 4 mg/mL, yet more preferably 32.5 ⁇ 3 mg/mL, most preferably 32.5 ⁇ 2 mg/mL, and in particular 32.5 ⁇ 1 mg/mL, based on the total volume of the composition.
• the concentration of tapentadol is within the range of 35 ⁇ 6 mg/mL, more preferably 35 ⁇ 5 mg/mL, still more preferably 35 ⁇ 4 mg/mL, yet more preferably 35 ⁇ 3 mg/mL, most preferably 35 ⁇ 2 mg/mL, and in particular 35 ⁇ 1 mg/mL, based on the total volume of the composition.
• the composition does not contain any preservative.
• a “preservative” preferably refers to any substance that is usually added to pharmaceutical compositions in order to preserve them against microbial degradation or microbial growth.
• microbial growth typically plays an essential role, i.e. the preservative serves the main purpose of avoiding microbial contamination.
• preservatives include benzalkonium chloride, benzethonium chloride, benzoic acid, sodium benzoate, benzyl alcohol, bronopol, cetrimide, cetylpyridinium chloride, chlorhexidine, chlorbutanol, chlorocresol, chloroxylenol, cresol, ethyl alcohol, glycerin, hexetidine, imidurea, phenol, phenoxyethanol, phenylethyl alcohol, phenylmercuric nitrate, propylene glycol, sodium propionate, thimerosal, methyl paraben, ethyl paraben, propyl paraben, butyl paraben, isobutyl paraben, benzyl paraben, sorbic acid, and potassium sorbate.
• Sodium benzoate is particularly preferred.
• the concentration of tapentadol is at least 10 mg/mL, at least 12.5 mg/mL, at least 15 mg/mL, or at least 17.5 mg/mL, based on the total volume of the composition.
• the pH value of the aqueous composition is sufficiently high so that due to its preservative property the desired shelf life or in use stability can be achieved by the presence of the drug itself.
• the pH value of the composition is at least 3.0, at least 3.5, at least 4.0, or at least 4.5 mg/mL.
• shelf life preferably refers to the storage stability of a closed container of the pharmaceutical composition.
• In-use stability preferably refers to the storage container that contains a multiple dose preparation which has been utilized for the first time. Typically, the shelf-life of a multiple dose preparation is much longer than its in-use stability.
• the composition additionally contains a preservative, which is preferably selected from the group consisting of benzalkonium chloride, benzethonium chloride, benzoic acid, sodium benzoate, benzyl alcohol, bronopol, cetrimide, cetylpyridinium chloride, chlorhexidine, chlorbutanol, chlorocresol, chloroxylenol, cresol, ethyl alcohol, glycerin, hexetidine, imidurea, phenol, phenoxyethanol, phenylethyl alcohol, phenylmercuric nitrate, propylene glycol, sodium propionate, thimerosal, methyl paraben, ethyl paraben, propyl paraben, butyl paraben, isobutyl paraben, benzyl paraben, sorbic acid, and potassium sorbate.
• a preservative which is preferably selected from the group consisting of benzalkonium chloride, benze
• aqueous tapentadol compositions containing sodium benzoate show a lower decrease in preservative at 50° C. and less degradation products compared with aqueous tapentadol compositions containing parabens.
• sodium benzoate is a particularly preferred preservative according to the invention.
• the content of the preservative is at most 5.0 wt.-%, more preferably at most 4.0 wt.-%, still more preferably at most 3.0 wt.-%, yet more preferably at most 2.0 wt.-%, most preferably at most 1.0 wt.-% and in particular at most 0.5 wt.-%, based on the total weight of the composition.
• the preservative preferably benzoic acid or its sodium salt
• the preservative has a concentration within the range of 1.0 ⁇ 0.6 mg/mL, more preferably 1.0 ⁇ 0.5 mg/mL, still more preferably 1.0 ⁇ 0.4 mg/mL, yet more preferably 1.0 ⁇ 0.3 mg/mL, most preferably 1.0 ⁇ 0.2 mg/mL, and in particular 1.0 ⁇ 0.1 mg/mL, based on the total volume of the composition.
• the preservative preferably benzoic acid or its sodium salt
• the preservative has a concentration within the range of 1.5 ⁇ 0.6 mg/mL, more preferably 1.5 ⁇ 0.5 mg/mL, still more preferably 1.5 ⁇ 0.4 mg/mL, yet more preferably 1.5 ⁇ 0.3 mg/mL, most preferably 1.5 ⁇ 0.2 mg/mL, and in particular 1.5 ⁇ 0.1 mg/mL, based on the total volume of the composition.
• the preservative preferably benzoic acid or its sodium salt
• the preservative preferably benzoic acid or its sodium salt
• the additional presence of a preservative in the composition is preferred when the content of tapentadol is too low so that due to its preservative property the desired shelf life or in use stability cannot be achieved by the presence of the drug itself.
• the preservative property of tapentadol is a function of the pH value and thus, at one pH value the addition of another preservative might be necessary, whereas at another pH value it can be completely omitted.
• the concentration of tapentadol is at most 12.5 mg/mL, at most 10 mg/mL, at most 8 mg/mL, at most 7.5 mg/mL, at most 5.0 mg/mL, at most 4.0 mg/mL, at most 3.0 mg/mL or at most 2.5 mg/mL, based on the total volume of the composition.
• the relative weight ratio of tapentadol to the preservative is within the range of from 10:1 to 0.25:1, more preferably 9:1 to 0.33:1, still more preferably 8:1 to 0.5:1, yet more preferably 7:1 to 0.66:1, most preferably 6:1 to 0.75:1 and in particular 5:1 to 1:1.
• the relative weight ratio of tapentadol to the preservative is within the range of from 5:1 to 1:1, more preferably 4.5:1 to 1:1, still more preferably 4:1 to 1:1, yet more preferably 3.5:1 to 1:1, most preferably 3:1 to 1:1 and in particular 2.5:1 to 1:1.
• the sum of the concentration of tapentadol and the concentration of preservative is equal or below 50 mg/mL, preferably equal or below 20 mg/mL, based on the total volume of the composition.
• the sum of the concentration of tapentadol and the concentration of preservative is within the range of 4.0 ⁇ 3.5 mg/mL, more preferably 4.0 ⁇ 3.0 mg/mL, still more preferably 4.0 ⁇ 2.5 mg/mL, yet more preferably 4.0 ⁇ 2.0 mg/mL, most preferably 4.0 ⁇ 1.5 mg/mL, and in particular 4.0 ⁇ 1.0 mg/mL, based on the total volume of the composition.
• the sum of the concentration of tapentadol and the concentration of preservative is within the range of 6.0 ⁇ 3.5 mg/mL, more preferably 6.0 ⁇ 3.0 mg/mL, still more preferably 6.0 ⁇ 2.5 mg/mL, yet more preferably 6.0 ⁇ 2.0 mg/mL, most preferably 6.0 ⁇ 1.5 mg/mL, and in particular 6.0 ⁇ 1.0 mg/mL, based on the total volume of the composition.
• the sum of the concentration of tapentadol and the concentration of preservative is within the range of 8.0 ⁇ 3.5 mg/mL, more preferably 8.0 ⁇ 3.0 mg/mL, still more preferably 8.0 ⁇ 2.5 mg/mL, yet more preferably 8.0 ⁇ 2.0 mg/mL, most preferably 8.0 ⁇ 1.5 mg/mL, and in particular 8.0 ⁇ 1.0 mg/mL, based on the total volume of the composition.
• the content of the preservative is at most 90%, more preferably at most 80%, still more preferably at most 70%, yet more preferably at most 60%, most preferably at most 50% and in particular at most 40% of the content that would be needed according to Ph. Eur. in order to sufficiently preserve the pharmaceutical composition in the absence of tapentadol, either concerning its shelf-life or, in case of multiple dosed preparations, optionally concerning its in-use stability. Sufficient preservation according to Ph. Eur. is preferably defined as in the experimental section (e.g. for molds and yeasts log reduction of 1 after 14 and no increase after 28 days).
• the composition according to the invention exhibits an antimicrobial robustness that complies with the requirements of the Ph. Eur., preferably in its version for 2010.
• antimicrobial robustness is achieved against E. coli, S. aureus, Ps. Aeruginosa, S. spp., C. albicans, and/or A. niger, preferably satisfying the requirement of log reduction of 1 after 14 and no increase after 28 days.
• antimicrobial robustness is achieved against bacteria satisfying the requirement of log reduction of 3 after 14 days and against molds and yeast of log reduction of 1 after 14 days.
• the composition according to the invention exhibits a shelf-life under accelerated storage conditions of at least 1 month, more preferably at least 2 months, still more preferably at least 3 months, yet more preferably at least 4 months, most preferably at least 5 months and in particular at least 6 months.
• the shelf life is determined according to Ph. Eur., particularly as described in the experimental section. Accelerated storage conditions preferably mean 40° C./75% relative humidity.
• the composition according to the invention exhibits a shelf-life under ambient conditions of at least 6 month, more preferably at least 12 months, still more preferably at least 15 months, yet more preferably at least 18 months, most preferably at least 21 months and in particular at least 24 months.
• the composition according to the invention is a multiple dosed preparation that exhibits an in-use stability under ambient conditions of at least 1 week, more preferably at least 2 weeks, still more preferably at least 3 weeks, yet more preferably at least 4 weeks, most preferably at least 5 weeks and in particular at least 6 weeks.
• the composition according to the invention is liquid or semisolid.
• the composition according to the invention is selected from the group consisting of syrups, drops, solutions, dispersions, suspensions and emulsions.
• Emulsions may be of o/w-type (oil-in-water) or w/o-type (water-in-oil).
• the pharmaceutical composition when it is a solution, it may be selected from the group consisting of aromatic waters, aqueous acids, diluted acids, douches, enemas, gargles, mouthwashes, juices, and irrigation solutions.
• the composition belongs to the group of sweet and other viscid aqueous solutions encompassing syrups, honeys, mucilages, and jellies.
• compositions according to the invention include collodions, elixirs, glycerins, liniments and spirits.
• the composition according to the invention is an emulsion, preferably selected from the group consisting of conventional emulsions, multiple emulsions, microemulsions and liposomes.
• composition according to the invention is a suspension, preferably selected from the group consisting of sustained release suspensions, gels and magmas, and lotions.
• the composition is a multiple dosed form, i.e. customized for more than a single administration.
• multiple dosed preferably means that the composition encompasses more than a single dosage unit.
• the composition is a multiple dosed oral solution, its overall volume is more than the volume that is to be typically orally administered at once. Instead, the multiple dosed oral solution is customized for being divided into a multitude of dosage units that are to be administered over a treatment interval typically encompassing several days.
• the multiple dosed oral dosage form that is contained in a storage container has a total volume of 250 mL and the prescribed dosage unit is 25 mL once daily
• the patient takes 25 mL so that 225 mL remain in the storage container
• the patient takes another 25 mL so that 200 mL remain in the storage container
• the entire amount is taken by the patient.
• composition according to the invention is ready to use, i.e. does not require particular treatment steps such as dissolution in a solvent before it may be orally administered to the patient.
• aqueous composition according to the invention may alternatively be commercialized as a precursor in form of a dry powder that is to be dissolved or dispersed in an appropriate amount of water prior to the first use.
• the composition according to the invention additionally comprises a taste-enhancing component.
• the taste-enhancing component comprises at least one sweetener, preferably selected from the group comprising cyclamate (E 952), saccharin (E 954) or sodium saccharin, aspartame (E 951), sucralose (E 955), neotame, thaumatine (E 957), neohesperidine (E 959), acesulphame potassium (acesulphame K, E 950) and acesulphame-aspartame salt (E 962), and sorbitol (E 420).
• Sucralose is particularly preferred.
• the content of the sweetener amounts to preferably ⁇ 20% by wt., more preferably ⁇ 15% by wt., still more preferably ⁇ 10% by wt., most preferably ⁇ 5.0% by wt., and in particular ⁇ 1.0%, based on the total weight of the composition.
• the concentration of the sweetener is within the range of 2.0 ⁇ 1 .5 mg/mL, more preferably 2.0 ⁇ 1.25 mg/mL, still more preferably 2.0 ⁇ 1.0 mg/mL, yet more preferably 2.0 ⁇ 0.75 mg/mL, most preferably 2.0 ⁇ 0.5 mg/mL, and in particular 2.0 ⁇ 0.25 mg/mL, based on the total volume of the composition.
• the concentration of the sweetener is within the range of 2.5 ⁇ 1.5 mg/mL, more preferably 2.5 ⁇ 1.25 mg/mL, still more preferably 2.5 ⁇ 1.0 mg/mL, yet more preferably 2.5 ⁇ 0.75 mg/mL, most preferably 2.5 ⁇ 0.5 mg/mL, and in particular 2.5 ⁇ 0.25 mg/mL, based on the total volume of the composition.
• the taste-enhancing component comprises at least one flavoring agent.
• Flavoring agents are known to the person skilled in the art. In this context, reference can be made, for example, to the European Commission: Decision of the Commission concerning a register of flavouring agents used in or on foodstuffs, of 23 Feb. 1999; last consolidated version dated 29.03.06. Natural or nature-identical flavorings of fruit are particularly preferred. Examples of suitable flavoring agents are orange flavor, blood orange flavor, lemon flavor, lime flavor, grapefruit flavor, strawberry flavor, raspberry flavor, blackcurrant flavor, redcurrant flavor, pineapple flavor, blueberry flavor, cherry flavor, woodruff flavor, vanilla flavor and mixtures thereof, such as wild berry flavor or strawberry-vanilla flavor. Raspberry flavor is particularly preferred.
• the concentration of the flavoring agent is within the range of 2.0 ⁇ 1.5 mg/mL, more preferably 2.0 ⁇ 1.25 mg/mL, still more preferably 2.0 ⁇ 1.0 mg/mL, yet more preferably 2.0 ⁇ 0.75 mg/mL, most preferably 2.0 ⁇ 0.5 mg/mL, and in particular 2.0 ⁇ 0.25 mg/mL, based on the total volume of the composition.
• compositions may include one or more further excipients selected from the group comprising wetting agents, emulsifying agents, isotonizing agents, surfactant components, solubilizing agents, thickening agents, colorant agents, and antioxidant components.
• a wetting agent or surfactant component can be included in the liquid compositions of the present invention that, when used, includes one or more quaternary ammonium compounds, such as benzalkonium chloride, benzethonium chloride and cetylpyridinium chloride; TPGS, dioctyl sodium sulfosuccinate; polyoxyethylene alkylphenyl ethers, such as nonoxynol 9, nonoxynol 10, and octoxynol 9; poloxamers (polyoxyethylene and polyoxypropylene block copolymers); polyoxyethylene fatty acid glycerides and oils, such as polyoxyethylene (8) caprylic/capric mono- and diglycerides, polyoxyethylene (35) castor oil and polyoxyethylene (40) hydrogenated castor oil; polyoxyethylene alkyl ethers, such as polyoxyethylene (20) cetostearyl ether; polyoxyethylene fatty acid esters, such as polyoxyethylene (40) stearate; polyoxyethylene
• Such surfactant component or wetting agent will typically together form about 0.25 wt.-% to about 15 wt.-%, preferably about 0.4 wt.-% to about 10 wt.-%, and more preferably about 0.5 wt.-% to about 5 wt.-%, of the total weight of the composition.
• a thickening agent or viscosity-enhancing agent can be included to generally thicken the liquid composition, which typically improves the mouth-feel of the composition, and/or to help coat the lining of the gastrointestinal tract.
• a preferred thickening agent when used, includes one or more of acacia, alginic acid bentonite, carbomer, carboxymethyl-cellulose calcium or sodium, cetostearyl alcohol, methyl cellulose, ethylcellulose, glycerin, gelatin guar gum, hydroxyethylcellulose, hydroxypropylcellulose, hydroxypropylmethyl-cellulose, maltodextrin, polyvinyl alcohol, povidone, propylene carbonate, propylene glycol alginate, sodium alginate, sodium starch glycolate, starch tragacanth, and xanthan gum, and any combination thereof.
• More preferred thickening agents are glycerin, hydroxypropylmethylcellulose, and xanthan gum, and any combination thereof.
• Such a thickening agent if present, will typically form about 0.1 wt.-%to 20 wt.-%, preferably about 0.3 wt.-%to about 15 wt.-%, and more preferably about 0.5 wt.-%to 4 wt.-%, of the total weight of the composition.
• a colorant agent when included, can provide the compositions with a more aesthetic and/or distinctive appearance.
• Colorant agents preferable for inclusion in the present invention include one or more water-soluble synthetic organic food additives (e.g., food dyes such as food red dye Nos. 2 and 3, food yellow dye Nos. 4 and 5 and food blue dye Nos. 1 and 2), water-insoluble lake dyes (e.g., aluminum salts of the above water-soluble synthetic organic food additives, etc.), and natural pigments (e.g., beta-carotene, chlorophyll, iron oxide red, etc.).
• water-soluble synthetic organic food additives e.g., food dyes such as food red dye Nos. 2 and 3, food yellow dye Nos. 4 and 5 and food blue dye Nos. 1 and 2
• water-insoluble lake dyes e.g., aluminum salts of the above water-soluble synthetic organic food additives, etc.
• natural pigments e.g., beta-carotene, chlorophyll, iron oxide
• Such a colorant agent if present, will typically form about 0.001 wt.-% to about 1 wt.-%, preferably about 0.001 wt.-% to about 0.5 wt.-%, and more preferably about 0.0075 wt.-% to about 0.25 wt.-%, of the total weight of the composition.
• a suitable antioxidant component examples include one or more of the following: sulfites; ascorbic acid; ascorbates, such as sodium ascorbate, calcium ascorbate, or potassium ascorbate; ascorbyl palmitate; fumaric acid; ethylene diamine tetraacetic acid (EDTA) or its sodium or calcium salts; tocopherol; gallates, such as propyl gallate, octyl gallate, or dodecyl gallate; vitamin E; and mixtures thereof.
• the antioxidant component provides long term stability to the liquid compositions. Addition of the antioxidant component can help enhance and ensure the stability of the compositions and renders the compositions stable even after six months at 40° C.
• a suitable amount of the antioxidant component, if present, is about 0.01 wt.-% to about 3 wt.-%, preferably about 0.05 wt.-% to about 2 wt.-%, of the total weight of the composition.
• Solubilizing and emulsifying agents can be included to facilitate more uniform dispersion of the active ingredient or other excipient that is not generally soluble in the liquid carrier.
• a suitable emulsifying agent includes, for example, gelatin, egg yolk, casein, cholesterol, acacia, tragacanth, chondrus, pectin, methyl cellulose, carbomer, cetostearyl alcohol, cetyl alcohol, and mixtures thereof.
• solubilizing agent examples include glycol, glycerin, D-mannitol, trehalose, benzyl benzoate, ethanol, trisaminomethane, cholesterol, triethanolamine, sodium carbonate, sodium citrate, sodium salicylate, sodium acetate, and mixtures thereof.
• the solubilizing agent includes glycerin.
• the solubilizing or emulsifying agent is/are generally present in an amount sufficient to dissolve or disperse the active ingredient, i.e. tapentadol, in the carrier.
• Typical amounts when a solubilizing or an emulsifier are included are from about 1 wt.-% to about 80 wt.-%, preferably about 20 wt.-% to about 65 wt.-%, and more preferably about 25 wt.-% to about 55 wt.-%, of the total weight of the composition.
• a suitable isotonizing agent includes sodium chloride, glycerin, D-mannitol, D-sorbitol, glucose, and mixtures thereof.
• a suitable amount of the isotonizing agent, when included, is typically about 0.01 wt.-% to about 15 wt.-%, more preferably about 0.3 wt.-% to about 4 wt.-%, and more preferably about 0.5 wt.-% to about 3 wt.-%, of the total weight of the composition.
• E 1 E 2 E 3 E 4 tapentadol ⁇ 50 mg/mL ⁇ 50 mg/mL ⁇ 30 mg/mL ⁇ 30 mg/mL buffer optional 0-5.0 0.001-4.0 wt. % 0.05-2.5 wt. % 0.05-2.5 wt. % preservative wt. % optional 0-3.0 wt. % 0-1.0 wt. % — taste-enhancing sweetener and/or ⁇ 1.0 wt. % 2.0 ⁇ 1.5 mg/mL component flavoring agent sweetener sweetener and and ⁇ 1.0 wt. % 2.0 ⁇ 1.5 mg/mL flavoring agent flavoring agent water ⁇ 5 wt. % ⁇ 50 wt.
• F 1 F 2 F 3 F 4 tapentadol 4.7 ⁇ 4.2 mg/mL 4.7 ⁇ 2.1 mg/mL 4.7 ⁇ 4.2 mg/mL 4.7 ⁇ 2.1 mg/mL buffer (pH 3.5-4.5) 1.7 ⁇ 1.5 mg/mL 1.7 ⁇ 0.8 mg/mL 1.7 ⁇ 1.5 mg/mL 1.7 ⁇ 0.8 mg/mL citric acid or its citric acid or its citric acid or its monohydrate monohydrate monohydrate monohydrate monohydrate preservative 2.4 ⁇ 2.0 mg/mL 2.4 ⁇ 1.0 mg/mL 2.4 ⁇ 2.0 mg/mL 2.4 ⁇ 1.0 mg/mL sodium benzoate sodium benzoate taste-enhancing 2.0 ⁇ 1.7 mg/mL 2.0 ⁇ 0.8 mg/mL 2.0 ⁇ 1.7 mg/mL 2.0 ⁇ 0.8 mg/mL component sweetener and sweetener and sucralose and sucralose and 2.0 ⁇ 1.7 mg/mL 2.0 ⁇ 0.8 mg/mL 2.0 ⁇
• a further aspect of the invention relates to a pharmaceutical dosage form comprising the pharmaceutical composition according to the invention. All preferred embodiments that are described above in connection with the composition according to the invention also apply to the dosage form according to the invention.
• the dosage form is selected from the group consisting of oral solutions, oral gels, suspensions, emulsions, liquid or gel filled capsules, liquid-filled lozenges, metered liquid dosing devices, atomizers, nebulizers, sprays, and liquid-releasing, edible capsules.
• liquid dosage forms Compared to solid dosage forms, liquid dosage forms have several advantages. They can be exactly dose, e.g. according to the body weight of the patients, which can be particularly important in pediatric patients. Further, they can be administered by means of probes, e.g. when the patient is young or has problems to swallow.
• liquid dosage forms tend to have a faster release, i.e. the concentration of the active ingredient in the serum or plasma increases faster than after adminsitration of a solid dosage form (rapid onset), even if the solid dosage form is qualified as immediate release disage form (IR).
• rapid onset is particularly desirable in the treatment of pain, since pain relief is to be achieved as fast as possible.
• the dosage form according to the invention is adapted for administration once daily, twice daily, thrice daily, four times daily, five times daily, six times daily or even more frequently.
• the dosage form according to the invention is adapted for administration to pediatric patients.
• pediatric patients preferably encompass infants, children, and adolescents.
• the upper age limit of such patients is 12, 13, 14, 15, 16, 17, 18, 19, 20 or 21.
• tapentadol is suitable for treating pain in patients suffering from serious diseases, e.g. for treating cancer pain, such patients including pediatric patients are usually simultaneously treated with other medicaments, e.g. chemotherapeutics, that have severe side effects. Under these circumstances, it is even more desirable to not expose such pediatric patients to preservatives, if avoidable.
• a further aspect of the invention relates to the pharmaceutical composition according to the invention as described above or the pharmaceutical dosage form according to the invention as described above for use in the treatment of pain.
• a still further aspect of the invention relates to the use of tapentadol for the manufacture of the pharmaceutical composition according to the invention as described above or of the pharmaceutical dosage form according to the invention as described above for the treatment of pain.
• a yet further aspect of the invention relates to a method for the treatment of pain comprising the oral administration of the pharmaceutical composition according to the invention as described above or of the pharmaceutical dosage form according to the invention as described above to a subject in need thereof.
• the pain is selected from the group consisting of inflammatory pain, neuropathic pain, acute pain, chronic pain, visceral pain, migraine pain and cancer pain.
• Another aspect of the invention relates to the use of tapentadol or a physiologically acceptable salt thereof as preservative.
• tapentadol hydrochloride at a concentration of 10 mg/mL free base exhibits a high antimicrobial activity and a high activity against yeast.
• the activity against mold Aspergillus niger ) is lower but still within the limits of the requirements of the Pharm. Eur.
• the activity of tapentadol hydrochloride against Aspergillus niger has been evaluated at lower drug concentrations and at pH 4.0 and 5.0 in formulations containing citric acid as buffer system and hydrochloric acid and sodium hydroxide to adjust the pH.
• tapentadol At pH 4 minimal concentration of 8 mg/mL tapentadol is needed to meet the requirements of the Eur. Pharm. with regard to Aspergillus niger . There is a concentration limit of 4-8 mg/mL for antimicrobial effectiveness of tapentadol depending on the pH.
• the 20 mg/mL solution of tapentadol has been subjected to an antimicrobial robustness testing.
• the antimicrobial activity of the formulation was determined at 100% and 90% of drug substance at three different pH levels (target, upper and lower limit—3.5-4-4.5).
• the following compositions of the formulation were used for the antimicrobial robustness testing (Table 2):
• the effect on A. niger is lower but meets for both concentrations the requirements of the Pharm. Eur. and USP, showing the overall spectrum of tapentadol hydrochloride as a preservative.
• the 4 mg/mL solution of tapentadol has also been subjected to an antimicrobial robustness testing.
• this concentration the antimicrobial effect of the drug substance tapentadol hydrochloride is not sufficiently pronounced. Therefore, sodium benzoate has been used as a preservative in the formulation.
• the antimicrobial activity of the formulation was determined with 100% at target pH of 4 and with 80% of sodium benzoate at the pH limits of 3.5 and 4.5.
• the following compositions of the formulation were used for the antimicrobial robustness testing (Table 3).
• the formulation containing sodium benzoate showed less degradation products compared with the parabens formulation. Therefore, sodium benzoate was used as selected preservative for further development.
• a tapentadol solution with a concentration of 15 mg/mL tapentadol (free base) was prepared.
• the pH-value was adjusted to the target value of 3 or 8 using citric acid and 1N NaOH solution, respectively. No additional buffer system was added.
• a placebo solution pH 8 was prepared, with focus on the same pH-value, even though a different amount of 1N NaOH solution was used for pH adjustment.
• the formulations were prepared, filled in glass bottles and sterilized in an autoclave for 30 min at 121° C. and 2 bars.
• the sterilized glass bottles were spiked with Staphylococcus aureus ( Staph. aureus ), Pseudomonas aeruginosa ( Ps. aerouginosa ), Aspergillus niger ( Asp. niger ) and Candida albicans for the test “Efficacy of antimicrobial preservation” on the basis of Ph. Eur. 6.6 monograph 5.1.3.
• the A criteria express the recommended efficacy to be achieved, in justified cases where the A criteria cannot be attained for example for reasons of an increased risk of adverse reaction, the B criteria must be satisfied.
• the test points at 6 and 24 hours were replaced by a test point at 30 min (table 5).
• the tapentadol solution pH 3 is not sufficiently preserved according to Ph. Eur. (crit. A and B) for Asp. niger and Cand. albicans , whereas the tapentadol solution pH 8 passed the crit. A and B for all tested bacteria and funghi.
• the placebo pH 8 solution shows no preservative effect of the solution itself, so that the antimicrobial effect of the formulation containing tapentadol HCl is a consequence of the added amount of tapentadol HCl. Considering this results a clear dependency of the pH-value on the preserving effect of the tapentadol HCl solution could be shown.
• the tapentadol HCl solution with a higher pH value of 8 has an improved antimicrobial effect compared to the pH 3 solution, so a clear dependency of the pH—value of the solution on the preserving effect of tapentadol was found.

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Pharmacology & Pharmacy (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Medicinal Chemistry (AREA)
• Epidemiology (AREA)
• General Chemical & Material Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Engineering & Computer Science (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Organic Chemistry (AREA)
• Oil, Petroleum & Natural Gas (AREA)
• Emergency Medicine (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Biomedical Technology (AREA)
• Neurology (AREA)
• Neurosurgery (AREA)
• Nutrition Science (AREA)
• Physiology (AREA)
• Pain & Pain Management (AREA)
• Inorganic Chemistry (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Rheumatology (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
• Medicinal Preparation (AREA)

Priority Applications (3)

Applications Claiming Priority (4)

Related Child Applications (1)

Publications (1)

Family

ID=44650617

Family Applications (3)

Family Applications After (2)

Country Status (23)

Cited By (4)

Families Citing this family (31)

Citations (5)

Family Cites Families (65)

• 2012
  • 2012-03-02 MX MX2013010101A patent/MX351584B/es active IP Right Grant
  • 2012-03-02 KR KR1020137026183A patent/KR101946790B1/ko active IP Right Grant
  • 2012-03-02 EP EP20154395.6A patent/EP3685827A1/en active Pending
  • 2012-03-02 EP EP19187973.3A patent/EP3597182A1/en active Pending
  • 2012-03-02 BR BR112013022495A patent/BR112013022495A2/pt not_active Application Discontinuation
  • 2012-03-02 US US13/410,768 patent/US20130022670A1/en not_active Abandoned
  • 2012-03-02 SI SI201231677T patent/SI2680832T1/sl unknown
  • 2012-03-02 EP EP17189271.4A patent/EP3287123B1/en not_active Revoked
  • 2012-03-02 RS RS20191382A patent/RS59491B1/sr unknown
  • 2012-03-02 PL PL17189271T patent/PL3287123T3/pl unknown
  • 2012-03-02 HU HUE12708672A patent/HUE046557T2/hu unknown
  • 2012-03-02 SI SI201231778T patent/SI3287123T1/sl unknown
  • 2012-03-02 LT LT12708672T patent/LT2680832T/lt unknown
  • 2012-03-02 EA EA201300989A patent/EA027290B1/ru not_active IP Right Cessation
  • 2012-03-02 CN CN201280011672.1A patent/CN103501773A/zh active Pending
  • 2012-03-02 MX MX2017007718A patent/MX369121B/es unknown
  • 2012-03-02 PT PT127086726T patent/PT2680832T/pt unknown
  • 2012-03-02 AU AU2012224952A patent/AU2012224952C1/en active Active
  • 2012-03-02 EA EA201692443A patent/EA035750B1/ru not_active IP Right Cessation
  • 2012-03-02 KR KR1020197003032A patent/KR102051800B1/ko active IP Right Grant
  • 2012-03-02 LT LTEP17189271.4T patent/LT3287123T/lt unknown
  • 2012-03-02 CA CA2828631A patent/CA2828631C/en active Active
  • 2012-03-02 EP EP12708672.6A patent/EP2680832B1/en active Active
  • 2012-03-02 JP JP2013555796A patent/JP6046057B2/ja active Active
  • 2012-03-02 PT PT171892714T patent/PT3287123T/pt unknown
  • 2012-03-02 PL PL12708672T patent/PL2680832T3/pl unknown
  • 2012-03-02 ES ES12708672T patent/ES2756776T3/es active Active
  • 2012-03-02 DK DK17189271.4T patent/DK3287123T3/da active
  • 2012-03-02 RS RS20200566A patent/RS60267B1/sr unknown
  • 2012-03-02 DK DK12708672.6T patent/DK2680832T3/da active
  • 2012-03-02 WO PCT/EP2012/000904 patent/WO2012119727A1/en active Application Filing
  • 2012-03-02 CN CN201710605686.0A patent/CN107308108A/zh active Pending
• 2013
  • 2013-08-06 IL IL227824A patent/IL227824B/en active IP Right Grant
  • 2013-08-28 ZA ZA2013/06478A patent/ZA201306478B/en unknown
• 2016
  • 2016-04-07 US US15/093,522 patent/US20160220516A1/en not_active Abandoned
  • 2016-11-15 JP JP2016222084A patent/JP6437984B2/ja active Active
  • 2016-12-13 AU AU2016273858A patent/AU2016273858B2/en active Active
• 2017
  • 2017-10-02 IL IL254854A patent/IL254854B/en unknown
• 2018
  • 2018-06-08 JP JP2018109967A patent/JP6735790B2/ja active Active
• 2019
  • 2019-10-01 HR HRP20191777TT patent/HRP20191777T1/hr unknown
  • 2019-10-10 CY CY20191101063T patent/CY1125100T1/el unknown
  • 2019-10-24 US US16/662,392 patent/US11547678B2/en active Active
• 2020
  • 2020-06-04 HR HRP20200898TT patent/HRP20200898T1/hr unknown
  • 2020-06-04 CY CY20201100500T patent/CY1123023T1/el unknown

Patent Citations (5)

Also Published As

Similar Documents

Legal Events